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The Histogenetic Model of Melanoma in the Modern 
Era of Personalized Medicine
Malignant melanoma (M) can be defined, quite sim-
ply, as a malignant neoplasm derived from melanocytes; 
however, there is great histological and, consequently, 
clinical variability from case to case (1). In order to try to 
overcome this intrinsic difficulty, various classification sys-
tems have been proposed over the years; as part of this 
effort, the World Health Organization (WHO) introduced 
its famous classification about half a century ago (2). Cur-
rently, the International Classification of Diseases for Oncol-
ogy (ICD-O), provided by the WHO International Agency for 
Research on Cancer (IARC), distinguishes the in situ forms 
from invasive ones, recognizing four main morphological 
subtypes: nodular M, superficial spreading M, lentigo ma-
ligna M, and acral lentiginous M (3). The ICD-O classifica-
tion includes further morphological codes, such as: balloon 
cell M, regressing M, amelanotic M, M in junctional nevus, 
M in precancerous melanosis, desmoplastic M, neurotropic 
M, mucosal lentiginous M, M in giant pigmented nevus / 
congenital melanocytic nevus, mixed epithelioid and spin-
dle cell M, epithelioid cell M, spindle cell M (not otherwise 
specified), spindle cell melanoma (type A), spindle cell M 
(type B), and malignant blue nevus (3). Alongside a strictly 
morphological classification, a histogenetic model, based 
on the concept of tumor progression, has been regaining 
ground (4,5). In fact, at the onset, M is characterized by a 
non-tumorigenic radial growth phase (RGP), inside the 
epidermis (intraepidermal) or within the papillary dermis 
(microinvasive), which is devoid of metastatic potential 
and which may be followed, early or late, by a tumorigenic 
vertical growth phase (VGP), with deeper extension in the 
dermis or beyond, nodular confluence, mitotic activity, and 
metastatic capacity (Table 1). The unique exception to this 
is nodular M, in which either RGP is rapidly overrun by VGP 
or the tumor arises directly from dermal melanocytes (6). 
Today, Breslow depth remains the single most important 
prognostic factor for clinically localized primary M: it allows 
us to distinguish M as ultra-thin (≤0.5 mm), thin (≤1 mm), 
thick (>1 mm), or ultra-thick (>6 mm) (7-10). The systematic 
application of the histogenetic model to Breslow depth al-
lows us to explain the oft-debated question why some thin 
M behave aggressively: because they possess an early tu-
morigenic VGP inside them (11). Moreover, any diagnostic 
report should be also accompanied by further well-known 
microstaging attributes, such as Clark level, mitotic count, 
lymphovascular invasion, perineural infiltration, ulceration, 
satellitosis, tumor infiltrating lymphocytes, and, if available, 
sentinel lymph node status (12,13). In conclusion, we be-
lieve that a renewed histogenetic approach to M diagnosis 
deserves wide scientific dissemination in order to achieve 
better clinical management of individual cases in the era of 
personalized medicine.
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